These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20179242)

  • 1. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.
    Huang H; Menefee M; Edgerly M; Zhuang S; Kotz H; Poruchynsky M; Huff LM; Bates S; Fojo T
    Clin Cancer Res; 2010 Mar; 16(5):1634-41. PubMed ID: 20179242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for microtubule target engagement in tumors of patients receiving ixabepilone.
    Zhuang SH; Hung YE; Hung L; Robey RW; Sackett DL; Linehan WM; Bates SE; Fojo T; Poruchynsky MS
    Clin Cancer Res; 2007 Dec; 13(24):7480-6. PubMed ID: 18094432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
    Posadas EM; Undevia S; Manchen E; Wade JL; Colevas AD; Karrison T; Vokes EE; Stadler WM
    Cancer Biol Ther; 2007 Apr; 6(4):490-3. PubMed ID: 17457044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
    Low JA; Wedam SB; Lee JJ; Berman AW; Brufsky A; Yang SX; Poruchynsky MS; Steinberg SM; Mannan N; Fojo T; Swain SM
    J Clin Oncol; 2005 Apr; 23(12):2726-34. PubMed ID: 15837987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.
    Burotto M; Edgerly M; Poruchynsky M; Velarde M; Wilkerson J; Kotz H; Bates S; Balasubramaniam S; Fojo T
    Oncologist; 2015 Jul; 20(7):725-6. PubMed ID: 26040622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
    Denduluri N; Low JA; Lee JJ; Berman AW; Walshe JM; Vatas U; Chow CK; Steinberg SM; Yang SX; Swain SM
    J Clin Oncol; 2007 Aug; 25(23):3421-7. PubMed ID: 17606971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
    Thomas E; Tabernero J; Fornier M; Conté P; Fumoleau P; Lluch A; Vahdat LT; Bunnell CA; Burris HA; Viens P; Baselga J; Rivera E; Guarneri V; Poulart V; Klimovsky J; Lebwohl D; Martin M
    J Clin Oncol; 2007 Aug; 25(23):3399-406. PubMed ID: 17606975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma.
    Burotto M; Edgerly M; Velarde M; Balasubramaniam S; Drabkin H; Gormaz JG; O'Sullivan C; Madan R; Fojo T
    Oncologist; 2017 Aug; 22(8):888-e84. PubMed ID: 28679644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.
    Zhuang SH; Agrawal M; Edgerly M; Bakke S; Kotz H; Thambi P; Rutt A; Balis FM; Bates S; Fojo T
    Cancer; 2005 May; 103(9):1932-8. PubMed ID: 15800893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.
    Ott PA; Hamilton A; Jones A; Haas N; Shore T; Liddell S; Christos PJ; Doyle LA; Millward M; Muggia FM; Pavlick AC
    PLoS One; 2010 Jan; 5(1):e8714. PubMed ID: 20098694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.
    De Geest K; Blessing JA; Morris RT; Yamada SD; Monk BJ; Zweizig SL; Matei D; Muller CY; Richards WE
    J Clin Oncol; 2010 Jan; 28(1):149-53. PubMed ID: 19917861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.
    Stein WD; Huang H; Menefee M; Edgerly M; Kotz H; Dwyer A; Yang J; Bates SE
    Cancer J; 2009; 15(5):441-7. PubMed ID: 19826366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
    Liu G; Chen YH; Dipaola R; Carducci M; Wilding G
    Clin Genitourin Cancer; 2012 Jun; 10(2):99-105. PubMed ID: 22386239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
    Roché H; Yelle L; Cognetti F; Mauriac L; Bunnell C; Sparano J; Kerbrat P; Delord JP; Vahdat L; Peck R; Lebwohl D; Ezzeddine R; Curé H
    J Clin Oncol; 2007 Aug; 25(23):3415-20. PubMed ID: 17606972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixabepilone, a novel epothilone analog in the treatment of breast cancer.
    Pivot X; Villanueva C; Chaigneau L; Nguyen T; Demarchi M; Maurina T; Stein U; Borg C
    Expert Opin Investig Drugs; 2008 Apr; 17(4):593-9. PubMed ID: 18363523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.
    Shimizu T; Yamamoto N; Yamada Y; Fujisaka Y; Yamada K; Fujiwara Y; Takayama K; Tokudome T; Klimovsky J; Tamura T
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):751-8. PubMed ID: 17594093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas.
    Churpek JE; Pro B; van Besien K; Kline J; Conner K; Wade JL; Hagemeister F; Karrison T; Smith SM
    Cancer; 2013 May; 119(9):1683-9. PubMed ID: 23310949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer.
    Denduluri N; Lee JJ; Walshe J; Berman AW; Vatas U; Chow CK; Steinberg SM; Cox MC; Low JA; Swain SM
    Invest New Drugs; 2007 Feb; 25(1):63-7. PubMed ID: 16933153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.